EULAR recommendations for the management of primary small and medium vessel vasculitis
- C Mukhtyar1,
- L Guillevin2,
- M C Cid3,
- B Dasgupta4,
- K de Groot5,
- W Gross6,
- T Hauser7,
- B Hellmich8,
- D Jayne9,
- C G M Kallenberg10,
- P A Merkel11,
- H Raspe6,
- C Salvarani12,
- D G I Scott13,
- C Stegeman10,
- R Watts14,
- K Westman15,
- J Witter16,
- H Yazici17,
- R Luqmani1,
- for the European Vasculitis Study Group
- 1University of Oxford, Oxford, UK
- 2University of Paris Descartes, Paris, France
- 3Hospital Clinic, Barcelona, Spain
- 4Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, UK
- 5Klinikum Offenbach, Offenbach, Germany
- 6University Hospital of Schleswig-Holstein, Lübeck, Germany
- 7University Hospital, Zurich, Switzerland
- 8Kreiskrankenhaus Plochingen, Plochingen, Germany
- 9Addenbrooke’s Hospital, Cambridge, UK
- 10University Medical Centre Groningen, Groningen, The Netherlands
- 11Boston University School of Medicine, Boston, Massachusetts, USA
- 12Arcispedale S Maria Nuova, Reggio Emilia, Italy
- 13Norfolk and Norwich University Hospital Trust, Norwich, UK
- 14Ipswich Hospital NHS Trust, Ipswich, UK
- 15Malmo University Hospital, Malmo, Sweden
- 16US Food and Drug Administration, Rockville, Maryland, USA
- 17University of Istanbul, Istanbul, Turkey
- R Luqmani, Nuffield Orthopaedic Centre, University of Oxford, Windmill Road, Oxford OX3 7LD, UK; raashid.luqmani{at}noc.anglox.nhs.uk
- Accepted 7 April 2008
- Published Online First 15 April 2008
Abstract
Objectives: To develop European League Against Rheumatism (EULAR) recommendations for the management of small and medium vessel vasculitis.
Methods: An expert group (consisting of 10 rheumatologists, 3 nephrologists, 2 immunologists, 2 internists representing 8 European countries and the USA, a clinical epidemiologist and a representative from a drug regulatory agency) identified 10 topics for a systematic literature search using a modified Delphi technique. In accordance with standardised EULAR operating procedures, recommendations were derived for the management of small and medium vessel vasculitis. In the absence of evidence, recommendations were formulated on the basis of a consensus opinion.
Results: In all, 15 recommendations were made for the management of small and medium vessel vasculitis. The strength of recommendations was restricted by low quality of evidence and by EULAR standardised operating procedures.
Conclusions: On the basis of evidence and expert consensus, recommendations have been made for the evaluation, investigation, treatment and monitoring of patients with small and medium vessel vasculitis for use in everyday clinical practice.
Footnotes
-
Competing interests: None declared.








